Comparative Pharmacology
Head-to-head clinical analysis: BENDEKA versus CISPLATIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENDEKA versus CISPLATIN.
BENDEKA vs CISPLATIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bendamustine is a bifunctional mechlorethamine derivative with alkylating and antimetabolite properties. It forms cross-links between DNA strands, leading to DNA synthesis inhibition and apoptosis. The exact mechanism also involves activation of p53-dependent and p53-independent stress pathways, and inhibition of mitotic checkpoints.
Platinum-based alkylating-like agent that forms intrastrand and interstrand DNA crosslinks, inhibiting DNA replication and transcription, leading to cell cycle arrest and apoptosis.
120 mg/m2 intravenously infused over 10 minutes on Days 1 and 2 of a 28-day cycle, up to 6 cycles.
50-100 mg/m² IV every 3-4 weeks; or 20 mg/m² IV daily for 5 days every 3-4 weeks.
None Documented
None Documented
Clinical Note
moderateCisplatin + Digoxin
"Cisplatin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateCisplatin + Digitoxin
"Cisplatin may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateCisplatin + Deslanoside
"Cisplatin may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateCisplatin + Acetyldigitoxin
"Cisplatin may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life is approximately 40 minutes for bendamustine; active metabolite (gamma-hydroxybendamustine) has half-life of about 3 hours. Clinical context: short half-life allows for rapid clearance, but requires frequent dosing.
The terminal elimination half-life is 20-30 hours (range 10-40 hours) in patients with normal renal function. This prolonged half-life is due to slow release of platinum from tissue binding and is clinically relevant for cumulative nephrotoxicity and ototoxicity.
Primarily renal excretion (approximately 50% as unchanged drug and metabolites); biliary/fecal elimination is minor (<5%).
Renal excretion accounts for 70-90% of cisplatin elimination, with approximately 20-50% excreted unchanged in the urine within 24 hours. Biliary/fecal excretion is minimal (<5%).
Category C
Category D/X
Alkylating Agent
Alkylating Agent